lactoferrin has been researched along with Hepatitis--Viral--Human* in 2 studies
1 review(s) available for lactoferrin and Hepatitis--Viral--Human
Article | Year |
---|---|
Viral Hepatitis and Iron Dysregulation: Molecular Pathways and the Role of Lactoferrin.
The liver is a frontline immune site specifically designed to check and detect potential pathogens from the bloodstream to maintain a general state of immune hyporesponsiveness. One of the main functions of the liver is the regulation of iron homeostasis. The liver detects changes in systemic iron requirements and can regulate its concentration. Pathological states lead to the dysregulation of iron homeostasis which, in turn, can promote infectious and inflammatory processes. In this context, hepatic viruses deviate hepatocytes' iron metabolism in order to better replicate. Indeed, some viruses are able to alter the expression of iron-related proteins or exploit host receptors to enter inside host cells. Lactoferrin (Lf), a multifunctional iron-binding glycoprotein belonging to the innate immunity, is endowed with potent antiviral activity, mainly related to its ability to block viral entry into host cells by interacting with viral and/or cell surface receptors. Moreover, Lf can act as an iron scavenger by both direct iron-chelation or the modulation of the main iron-related proteins. In this review, the complex interplay between viral hepatitis, iron homeostasis, and inflammation as well as the role of Lf are outlined. Topics: Animals; Biological Transport; Disease Resistance; Disease Susceptibility; Hepatitis, Viral, Human; Homeostasis; Host-Pathogen Interactions; Humans; Iron; Iron-Binding Proteins; Lactoferrin; Liver; Organ Specificity; Protein Binding; Receptors, Cell Surface | 2020 |
1 other study(ies) available for lactoferrin and Hepatitis--Viral--Human
Article | Year |
---|---|
Immunohistochemical evidence of lactoferrin in hepatic biopsies of patients with viral or cryptogenetic chronic liver disease.
Lactoferrin (Lf) expression has been immunohistochemically investigated in 117 formalin-fixed paraffin-embedded liver bioptic samples obtained from an equal number of patients affected by chronic hepatitis (HCV = 76; HBV = 17; HBV + HDV = 14; cryptogenetic = 10); in addition, 10 autoptic specimens of normal liver were studied as control. The Lf immunoreactivity was evaluated by an intensity-distribution (ID) score. The Lf immunoexpression was observed in 88 out of 117 (75%) cases of chronic hepatitis; interestingly, all liver specimens from HBV hepatitis showed a constant Lf reactivity with the highest ID-score, whereas the evidence of Lf was encountered in 54/76 (71.1%) HCV as well as in 11/14 (78.6%) HDV chronic hepatitis, thus documenting a variable degree of Lf immunostaining in relation to different viruses. Moreover, in 6/10 (60%) cases of cryptogenetic hepatitis Lf immunoexpression was documented, whereas all normal liver controls were unreactive. In HCV specimens, the Lf nuclear immunoreactivity appeared to increase with the progression of the disease, with a greater expression in genotype 1. In contrast, no relationship among Lf ID-scores and different stages or grades of HBV, HDV or cryptogenetic hepatitis was encountered. This fact may suggest a role for Lf as an unspecific defensive agent in chronic inflammatory liver diseases, similarly to that elsewhere reported in other inflammatory tissue injuries. Topics: Adult; Aged; Cell Nucleus; Coloring Agents; Cytoplasm; Female; Hepatitis; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis C; Hepatitis, Chronic; Hepatitis, Viral, Human; Hepatocytes; Humans; Immunohistochemistry; Lactoferrin; Liver; Male; Middle Aged | 2002 |